William Conkling

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: Joyce J Mason, by Power of Attorney
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for William Conkling

Form 4 holding Chief Executive Officer

Rafael Holdings, Inc.

Security class: Class B Common Stock, par value $.01 per share
Shares / value: 564,455
Estimated value: $1,055,643
Report date: 25 Mar 2025
Price: $1.87
Ownership: Direct

Form 4 holding Chief Executive Officer

Rafael Holdings, Inc.

Security class: Class B Common Stock, par value $.01 per share
Shares / value: 520,749
Estimated value: $757,690
Report date: 21 Jun 2024
Price: $1.46
Ownership: Direct

Form 4 holding Chief Commercial Officer

Protara Therapeutics, Inc.

Security class: Common Stock
Shares / value: 69,992
Estimated value: $364,658
Report date: 02 Jun 2026
Price: $5.21
Ownership: Direct

Form 4 holding Director

Cyclo Therapeutics, Inc.

Security class: Common Stock
Shares / value: 77,884
Estimated value: $49,067
Report date: 27 Feb 2025
Price: $0.6300
Ownership: Direct

Form 4 holding Director

IDT CORP

Security class: Class B Common Stock, $.01 par value per share
Shares / value: 673
Estimated value: $33,044
Report date: 09 Jun 2026
Price: $49.10
Ownership: Direct

Form 4 holding Chief Commercial Officer

Protara Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 158,000
Estimated value
Report date: 16 Jan 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Cyclo Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 15,562
Estimated value
Report date: 03 Jun 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Executive Officer

Rafael Holdings, Inc.

Security class: Employee Stock Option (right to buy)
Shares / value: 5,485
Estimated value
Report date: 25 Mar 2025
Price
Ownership: Direct
Underlying class: Class B Common Stock
Underlying amount

Insider Reports Filed by William Conkling

4 IDT

IDT CORP

Report period: 09 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 Jun 2026, 15:37
Role: Director
Next action: Open filing details

3 IDT

IDT CORP

Report period: 09 Jun 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 11 Jun 2026, 14:12
Role: Director
Next action: Open filing details

4 TARA

Protara Therapeutics, Inc.

Report period: 02 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Jun 2026, 16:55
Role: Chief Commercial Officer
Next action: Open filing details

4 TARA

Protara Therapeutics, Inc.

Report period: 16 Jan 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 21 Jan 2026, 16:37
Role: Chief Commercial Officer
Next action: Open filing details

4 TARA

Protara Therapeutics, Inc.

Report period: 02 Jun 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Jun 2025, 16:10
Role: Chief Commercial Officer
Next action: Open filing details

3 TARA

Protara Therapeutics, Inc.

Report period: 02 Jun 2025
Transactions: 0
Transaction value: $0
Accepted by SEC: 04 Jun 2025, 16:05
Role: Chief Commercial Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 25 Mar 2025
Transactions: 3
Transaction value: $0
Accepted by SEC: 24 Apr 2025, 15:18
Role: Chief Executive Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Mar 2025
Transactions: 1
Transaction value: -$28,591
Accepted by SEC: 25 Mar 2025, 16:39
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 27 Feb 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Mar 2025, 11:45
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 13 Jan 2025
Transactions: 1
Transaction value: +$117,240
Accepted by SEC: 15 Jan 2025, 14:22
Role: Chief Executive Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Dec 2024
Transactions: 1
Transaction value: -$23,501
Accepted by SEC: 23 Dec 2024, 15:27
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 15 Nov 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 18 Nov 2024, 14:11
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 25 Oct 2024
Transactions: 1
Transaction value: -$6,313
Accepted by SEC: 29 Oct 2024, 17:15
Role: Chief Executive Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Sep 2024
Transactions: 1
Transaction value: -$21,901
Accepted by SEC: 24 Sep 2024, 13:03
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 16 Aug 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Aug 2024, 13:49
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Jun 2024
Transactions: 1
Transaction value: -$19,344
Accepted by SEC: 25 Jun 2024, 14:50
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 03 Jun 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 05 Jun 2024, 17:07
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Mar 2024
Transactions: 1
Transaction value: +$26,381
Accepted by SEC: 25 Mar 2024, 09:40
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 13 Feb 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Feb 2024, 16:41
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Dec 2023
Transactions: 1
Transaction value: +$24,756
Accepted by SEC: 26 Dec 2023, 14:23
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 28 Nov 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 Nov 2023, 09:08
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 25 Oct 2023
Transactions: 1
Transaction value: +$60,600
Accepted by SEC: 26 Oct 2023, 16:10
Role: Chief Executive Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Sep 2023
Transactions: 1
Transaction value: -$30,140
Accepted by SEC: 22 Sep 2023, 09:10
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 18 Aug 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Aug 2023, 16:07
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Jun 2023
Transactions: 1
Transaction value: -$32,616
Accepted by SEC: 22 Jun 2023, 13:21
Role: Chief Executive Officer
Next action: Open filing details

4 CYTH

Cyclo Therapeutics, Inc.

Report period: 06 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Jun 2023, 20:46
Role: Director
Next action: Open filing details

3 CYTH

Cyclo Therapeutics, Inc.

Report period: 02 May 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 08 May 2023, 16:02
Role: Director
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Mar 2023
Transactions: 1
Transaction value: -$26,094
Accepted by SEC: 23 Mar 2023, 09:26
Role: Chief Executive Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 21 Dec 2022
Transactions: 1
Transaction value: -$98,822
Accepted by SEC: 23 Dec 2022, 09:02
Role: Chief Executive Officer
Next action: Open filing details

4 RFL

Rafael Holdings, Inc.

Report period: 01 Feb 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Feb 2022, 07:48
Role: Chief Executive Officer
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for William Conkling

Insider Reports Filed by William Conkling